Trials / Terminated
TerminatedNCT04235621
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Goldfinch Bio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | FSGS/TR-MCD | This is a non-interventional study |
| OTHER | Diabetic Nephropathy (DN) | This is a non-interventional study |
Timeline
- Start date
- 2019-12-20
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
- First posted
- 2020-01-22
- Last updated
- 2021-07-20
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04235621. Inclusion in this directory is not an endorsement.